Abbott Laboratories (ABT) recently reported its Q2 2024 earnings, surpassing estimates for both revenue and profit. The company has also increased its financial guidance for the full year, backed by high growth in medical device sales. Despite this, the company's stock has been trading lower and witnessed a significant drop in COVID-19 testing revenue. There has been a reduction in stock position by entities including Banco Santander S.A. and Nwam LLC. Despite a decline of 7% this year, analysts expect the stock to encounter higher levels post Q2 results. Abbott has also been in hot water recently over lawsuits regarding premature-baby formula. The Q2 results came in line with consensus estimates, causing a change in stock dynamics. Abbott has also undertaken a marketing push for its new glucose monitors targeting health-conscious consumers. Investor interest in the company appears to be rising, as suggested by heavy searches and share acquisitions.
Abbott Laboratories ABT News Analytics from Wed, 03 Jan 2024 08:00:00 GMT to Sun, 21 Jul 2024 16:54:35 GMT -
Rating 2
- Innovation 4
- Information 8
- Rumor -5
